Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 DOSING ONGOING AND PLANNED IN A HANDFUL OF OTHER SERIOUS DISEASES (OSD)   COMPANY PLANS TO PARTNER-OUT OTHER SERIOUS DISEASE PROGRAMS   ON TRACK FOR FIRST BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN LEAD INDICATION RELAPSED/REFRACTORY AL AMYLOIDOSIS  LOS ANGELES, CA, AUG. 06, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED IMPORTANT UPDATES ABOUT ITS PLAN TO ADDRESS OTHER SERIOUS DISEASES WITH ITS STERICALLY-OPTIMIZED BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY NXC-201 WITH A DIGITAL FILTER THAT FILTERS OUT NON-SPECIFIC ACTIVATION. THE COMPANY PLANS TO RELEASE FORTHCOMING CLINICAL DATA AT UPCOMING SCIENTIFIC FORUMS.

IMMIX BIOPHARMA ANNOUNCES OTHER SERIOUS DISEASES STRATEGY

 ABSENCE OF NEUROTOXICITY OF ANY GRADE IN LOW-VOLUME DISEASE TO-DATE   ON TRACK FOR FIRST BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN ORPHAN INDICATION RELAPSED/REFRACTORY AL AMYLOIDOSIS   POTENTIAL FUTURE INDICATION EXPANSION PLANNED  LOS ANGELES, JULY 11, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED A CLASS-LEADING SAFETY PROFILE FOR STERICALLY-OPTIMIZED CAR-T NXC-201, INCLUDING ABSENCE OF NEUROTOXICITY OF ANY GRADE IN LOW-VOLUME DISEASE TO-DATE, LAYING A FOUNDATION FOR POTENTIAL FUTURE INDICATION EXPANSION. WE ARE SINGULARLY FOCUSED ON COMPLETING NEXICART-2 FOR BLA SUBMISSION, WHERE WE ARE ACCELERATING PROGRESS.

IMMIX BIOPHARMA ANNOUNCES CLASS-LEADING SAFETY PROFILE, ALLOWING POTENTIAL FUTURE INDICATION EXPANSION

 NATIONAL FOOTPRINT OF NEXICART-2 TRIAL SITES EXPANDED   ON TRACK FOR FIRST BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN UNADDRESSED ORPHAN INDICATION   NEXICART-2 INTERIM RESULTS WERE PRESENTED AT ASCO 2025  LOS ANGELES, CA, JULY 07, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED ACCELERATED U.S. NEXICART-2 CLINICAL TRIAL PROGRESS IN RELAPSED/REFRACTORY AL AMYLOIDOSIS. NEXICART-2 NOW INCLUDES 18 CLINICAL TRIAL SITES IN ITS NATIONAL FOOTPRINT.

IMMIX BIOPHARMA ANNOUNCES ACCELERATED NEXICART-2 CLINICAL TRIAL PROGRESS IN RELAPSED/REFRACTORY AL AMYLOIDOSIS

 SELECTED TO ATTEND IN-PERSON EVENT ON JUNE 5 LED BY FDA COMMISSIONER MARTY A. MAKARY, M.D.

IMMIX BIOPHARMA ATTENDS FDA CEO FORUM IN WASHINGTON DC

IMMIX BIOPHARMA TODAY PRESENTED RESULTS AT ASCO FROM ITS U.S. MULTI-CENTER NEXICART-2 PHASE 1/2 CLINICAL TRIAL OF NXC-201, MEETING ITS PRIMARY ENDPOINT.

IMMIX BIOPHARMA ANNOUNCES PRIMARY ENDPOINT MET IN POSITIVE NXC-201 INTERIM RESULTS PRESENTED AT ASCO, ENABLING PATH TO BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

 PATIENT ENROLLMENT EXCEEDING EXPECTATIONS   14 U.S. SITES ACTIVELY ENROLLING; 10 U.S. SITES ADDED SINCE LAST UPDATE   ANTICIPATE COMPLETING NEXICART-2 CLINICAL TRIAL AHEAD OF SCHEDULE  LOS ANGELES, CA, MAY 23, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR "IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT 14 U.S. SITES ARE ACTIVELY ENROLLING IN U.S. MULTI-SITE STUDY NEXICART-2. THIS MILESTONE ADDS 10 SITES SINCE THE COMPANY'S MOST RECENT UPDATE.

IMMIX BIOPHARMA FURTHER EXPANDS U.S. CLINICAL SITES FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS TRIAL NEXICART-2

IMMIX BIOPHARMA TODAY REPORTED ASCO ABSTRACT RESULTS FROM ITS U.S. MULTI-CENTER NEXICART-2 PHASE 1/2 CLINICAL TRIAL OF NXC-201 DEMONSTRATING STRONG EFFICACY AND FAVORABLE SAFETY.

IMMIX BIOPHARMA ANNOUNCES POSITIVE RESULTS FOR NXC-201 AT ASCO ORAL PRESENTATION, ENABLING PATHWAY TO BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

 VIRTUAL KOL EVENT TUESDAY, JUNE 3, 2025 3:00PM ET   ATTEND THE EVENT HERE: HTTPS://LIFESCIEVENTS.COM/EVENT/IMMIX-ASCO  LOS ANGELES, CA, MAY 21, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL KEY OPINION LEADER (KOL) EVENT TO DISCUSS INTERIM CLINICAL DATA FROM THE NEXICART-2 PHASE 1/2 CLINICAL TRIAL OF CELL THERAPY NXC-201 IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS FOLLOWING ITS 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ORAL PRESENTATION IN CHICAGO, IL. THE VIRTUAL KOL EVENT WILL TAKE PLACE ON TUESDAY, JUNE 3, 2025 AT 3:00PM ET.

IMMIX BIOPHARMA TO HOST KOL EVENT TO DISCUSS NXC-201 CLINICAL DATA PRESENTED AT ASCO 2025 IN RELAPSED/REFRACTORY AL AMYLOIDOSIS

 ORAL PRESENTATION TUESDAY, JUNE 3, 2025 IN CHICAGO  LOS ANGELES, APRIL 23, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT PHASE 1/2 INTERIM READOUT DATA FROM ITS U.S. NXC-201 NEXICART-2 TRIAL IN RELAPSED/REFRACTORY AL AMYLOIDOSIS HAS BEEN SELECTED FOR ORAL PRESENTATION AT THE UPCOMING 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING (ASCO 2025) BEING HELD IN CHICAGO, ILLINOIS, MAY 30  JUNE 3, 2025, PRESENTED BY LEAD INVESTIGATOR HEATHER LANDAU, M.D., DIRECTOR OF AMYLOIDOSIS PROGRAM AND A BONE MARROW TRANSPLANT SPECIALIST & CELLULAR THERAPIST AT MEMORIAL SLOAN-KETTERING CANCER CENTER IN NEW YORK.

IMMIX BIOPHARMA'S NXC-201 NEXICART-2 CLINICAL TRIAL DATA SELECTED FOR ORAL PRESENTATION AT ASCO 2025

FDA RMAT DESIGNATION FOLLOWS POSITIVE PROOF-OF-CONCEPT U.S. CLINICAL DATA FROM THE NXC-201 NEXICART-2 CLINICAL TRIAL IN RELAPSED/REFRACTORY AL AMYLOIDOSIS RMAT DESIGNATION POTENTIALLY STREAMLINES THE PATH TO MARKET APPROVAL BY ALLOWING FREQUENT INTERACTIONS WITH FDA AND ROUTES TO FDA ACCELERATED APPROVAL AND PRIORITY REVIEW ENROLLMENT IN NEXICART-2 STUDY ACCELERATING; NEXT UPDATE PLANNED FOR H1 2025 LOS ANGELES,CA, FEB. 10, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (NASDAQ: IMMX) (IMMIXBIO, COMPANY, WE OR US, IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND SELECT IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED RMAT DESIGNATION TO STERICALLY-OPTIMIZED CAR-T NXC-201 FOR THE TREATMENT OF RELAPSED/REFRACTORY AL AMYLOIDOSIS. AS OF JUNE 2024 PUBLIC INFORMATION, FDA APPROVED LESS THAN HALF OF RMAT APPLICATIONS SUBMITTED TO THE AGENCY DURING THE LAST EIGHT YEARS.

IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR NXC-201, STERICALLY-OPTIMIZED CAR-T FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

Immix Biopharma, Inc.

IMMX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immix Biopharma, Inc.

IMMX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMMX